|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
OriGene Technologies Raises $21.3 Million in Series C Funding
3/21/2013 9:14:58 AM
ROCKVILLE, Md., March 21, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications, announced the completion of a $21.3 million Series C financing led by Qiming Venture Partners and Kleiner Perkins Caufield Byers China. OriGene's previous investorIDG-Accel also participated in this round. "We are pleased with the high level of commitment and enthusiasm from our new and existing investors. We intend to use the net proceeds from this financing to advance our growth strategy and operations," said Wei-Wu He, Ph.D., OriGene's Chairman and Chief Executive Officer. (Logo - http://photos.prnewswire.com/prnh/20130107/DC38100LOGO) About OriGene Technologies OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide. OriGene has developed an extensive array of ultra-specific monoclonal antibodies called UltraMAB which offers significant improvement over traditional antibodies. UltraMAB antibodies are validated by OriGene's proprietary high density microarray technology for a wide variety of antibody applications. For more information, visit www.origene.com. SOURCE OriGene Technologies, Inc.
|
|
|
|
|
|
|
|
|
|
|